Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib Diarrhea Management in HER2+ Breast Cancer
NCT03094052Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Oct 2018
- Primary completion
- Oct 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in HER2-positive breast cancer, sponsored by University of California, San Francisco. Started Oct 2018; status: completed.
02
Drugs
neratinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03094052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03094052.